GANSYMBI Trademark

Trademark Overview


On Wednesday, January 18, 2023, a trademark application was filed for GANSYMBI with the United States Patent and Trademark Office. The USPTO has given the GANSYMBI trademark a serial number of 97759284. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 2, 2024. This trademark is owned by Bristol-Myers Squibb Company. The GANSYMBI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
gansymbi

General Information


Serial Number97759284
Word MarkGANSYMBI
Filing DateWednesday, January 18, 2023
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 24, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events


Event DateEvent Description
Saturday, January 21, 2023NEW APPLICATION ENTERED
Tuesday, January 24, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 17, 2023ASSIGNED TO EXAMINER
Wednesday, July 26, 2023NON-FINAL ACTION WRITTEN
Wednesday, July 26, 2023NON-FINAL ACTION E-MAILED
Wednesday, July 26, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, October 25, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 25, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 26, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, October 28, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 5, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 30, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, September 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, December 5, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED